Details of the Drug Reposition

General Information of This Drug (ID: DMCGW5R)

Drug Name
Bavituximab   DMCGW5R
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 3 [1]
------------------------------------------------------------------------------------
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 2 [2]
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 2 [3]
Asthma DISW9QNS CA23 Phase 2 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01999673) Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8002).